Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
AssigneeYeda Research and Development Co. Ltd.
InventorsYosef Yarden, Michael Sela
Life of this patent
Estimating the term…
Abstract
A method of identifying a combination of antibodies with a combined improved anti tumor activity is provided. The method comprising identifying at least two anti RTK antibodies capable of inducing synergistic endocytosis of the RTK in a cell expressing the RTK, thereby identifying the combination of antibodies with the combined improved anti-tumor activity.
Claims12
An article of manufacture comprising a packaging material identified for treating cancer, packaging an anti-EGFR antibody comprising the CDR sequences of anti EGFR 111 and an anti-EGFR antibody comprising the CDR sequences of anti EGFR 565.
An article of manufacture comprising a packaging material identified for treating cancer, packaging an anti-EGFR antibody comprising the CDR sequences of anti EGFR 143 and an anti-EGFR antibody comprising the CDR sequences of anti EGFR 565.
An article of manufacture comprising a packaging material identified for treating cancer, packaging an anti-ErbB-2 antibody comprising the CDR sequences of Herceptin and an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L26.
A pharmaceutical composition comprising as active ingredients an anti-EGFR antibody comprising the CDR sequences of anti EGFR 111 and an anti-EGFR antibody comprising the CDR sequences of anti EGFR 565 and a pharmaceutically acceptable carrier or diluent.
A pharmaceutical composition comprising as active ingredients an anti-EGFR antibody comprising the CDR sequences of anti EGFR 143 and an anti-EGFR antibody comprising the CDR sequences of anti EGFR 565 and a pharmaceutically acceptable carrier or diluent.
A pharmaceutical composition comprising as active ingredients an anti-ErbB-2 antibody comprising the CDR sequences of Herceptin and an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L26 and a pharmaceutically acceptable carrier or diluent.
A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti-EGFR antibody comprising the CDR sequences of anti EGFR 111 and an anti-EGFR antibody comprising the CDR sequences of anti EGFR 565, thereby treating cancer in the subject.
A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti-EGFR antibody comprising the CDR sequences of anti EGFR 143 and an anti-EGFR antibody comprising the CDR sequences of anti EGFR 565, thereby treating cancer in the subject.
A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti-ErbB-2 antibody comprising the CDR sequences of Herceptin and an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L26, thereby treating cancer in the subject.
Dependencies are inferred from the claim text.